How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry

Sumant P. Radhoe, Jesse F. Veenis, Nina Jakus, Philippe Timmermans, Anne Catherine Pouleur, Pawel Rubís, Emeline M. Van Craenenbroeck, Edvinas Gaizauskas, Eduardo Barge-Caballero, Stefania Paolillo, Sebastian Grundmann, Domenico D'Amario, Oscar Braun, Aggeliki Gkouziouta, Ivo Planinc, Jure Samardzic, Bart Meyns, Walter Droogne, Karol Wierzbicki, Katarzyna HolcmanAndreas J. Flammer, Hrvoje Gasparovic, Bojan Biocina, Lars H. Lund, Davor Milicic, Frank Ruschitzka, Maja Cikes, Jasper J. Brugts*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
31 Downloads (Pure)


Aims: Use of left ventricular assist devices (LVADs) in older patients has increased, and assessing outcomes in older LVAD recipients is important. Therefore, this study aimed to investigate associations between age and outcomes after continuous-flow LVAD (cf-LVAD) implantation. Methods and results: Cf-LVAD patients from the multicentre European PCHF-VAD registry were included and categorized into those <50, 50–64, and ≥65 years old. The primary endpoint was all-cause mortality. Among secondary outcomes were heart failure (HF) hospitalizations, right ventricular (RV) failure, haemocompatibility score, bleeding events, non-fatal thromboembolic events, and device-related infections. Of 562 patients, 184 (32.7%) were <50, 305 (54.3%) were aged 50–64, whereas 73 (13.0%) were ≥65 years old. Median follow-up was 1.1 years. Patients in the oldest age group were significantly more often designated as destination therapy (DT) candidates (61%). A 10 year increase in age was associated with a significantly higher risk of mortality (hazard ratio [HR] 1.34, 95% confidence interval [CI] [1.15–1.57]), intracranial bleeding (HR 1.49, 95% CI [1.10–2.02]), and non-intracranial bleeding (HR 1.30, 95% CI [1.09–1.56]), which was confirmed by a higher mean haemocompatibility score (1.37 vs. 0.77, oldest vs. youngest groups, respectively, P = 0.033). Older patients suffered from less device-related infections requiring systemic antibiotics. No age-related differences were observed in HF-related hospitalizations, ventricular arrhythmias, pump thrombosis, non-fatal thromboembolic events, or RV failure. Conclusions: In the PCHF-VAD registry, higher age was associated with increased risk of mortality, and especially with increased risk of major bleeding, which is particularly relevant for the DT population. The risks of HF hospitalizations, pump thrombosis, ventricular arrhythmia, or RV failure were comparable. Strikingly, older patients had less device-related infections.

Original languageEnglish
Pages (from-to)884-894
Number of pages11
JournalESC heart failure
Issue number2
Early online date2 Dec 2022
Publication statusPublished - Apr 2023

Bibliographical note

Publisher Copyright:
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.


Dive into the research topics of 'How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry'. Together they form a unique fingerprint.

Cite this